# Stage 04 — Multimodal Integration Engineer Master Report
**Project**: Personalized Precision Medicine for Oncology Treatment Optimization  
**Author**: Integration Engineer (System Integration & Multimodal Verification)  
**Scope**: Unified Pipeline Connecting Stage 01 (ML), Stage 02 (DL), and Stage 03 (NLP)  

> [!IMPORTANT]
> **MANDATORY SYNTHETIC DATA & REGULATORY DISCLAIMER**:
> *Synthetic research integration only. This system is not clinically validated and must not be interpreted as evidence of clinical efficacy, diagnostic performance, or treatment recommendation.*
> All upstream stages (01 ML, 02 DL, 03 NLP) and the integration layer operate strictly on synthetic oncology research records. This software is a decision-support research prototype and is NOT an approved medical device.


---

## 1. Executive Summary
The Integration Engineer has designed, constructed, stress-tested, and validated the complete end-to-end multimodal integration subsystem in `STAGE_04_INTEGRATION/`.
All upstream models, datasets, and evaluation artifacts remained 100% READ-ONLY throughout execution.
The pipeline unites tabular ML, imaging/sequence DL, and clinical-text NLP into a coherent precision-medicine decision support framework.

## 2. Project Objective
Deliver a robust patient-level integration pipeline capable of operating across heterogeneous clinical modalities, handling missing evidence through principled weight renormalization, enforcing clinical safety overrides, and providing explainable decision support.

## 3. Upstream Stage Summary
- **Stage 01 ML**: XGBoost baseline tabular classifier (99.15% accuracy on 939 test patients).
- **Stage 02 DL**: Multimodal CNN + LSTM + MLP network (84.62% test accuracy on 26 test patients).
- **Stage 03 NLP**: BioClinicalBERT urgency classifier (89.17% accuracy) & BioBERT medical NER (0.9450 strict micro F1) on 3,740 test notes across 374 patients.

## 4. Stage 01 Integration
The Stage 01 adapter dynamically loads `test_eval_results.npz` and `SPLITS/test.csv`, formatting predictions into standard schema: `ml_prediction`, `ml_probability`, `ml_confidence`.

## 5. Stage 02 Integration
The Stage 02 adapter evaluates histopathology, longitudinal sequences, and deep tabular embeddings from `METADATA/patient_master.csv` and `SPLITS/test_manifest.csv`, aggregating multi-image observations via max-pooling.

## 6. Stage 03 Integration
The Stage 03 adapter aggregates encounter-level notes per patient, calculates probabilistic urgency distributions, and collates extracted `GENE_MUTATION`, `DRUG`, `DOSAGE`, and `ADVERSE_EVENT` spans.

## 7. Patient Alignment
Exact string ID matching identifies 157 shared ML+DL patients in full splits (24 in test split). To validate the full 3-modality pipeline under audit, an explicit, read-only benchmark crosswalk (`synthetic_benchmark_crosswalk.json`) links 24 test patients across matching cancer types.

## 8. Data Availability
Evidence levels are explicitly categorized as `FULL_MULTIMODAL`, `PARTIAL_MULTIMODAL`, and `SINGLE_MODALITY`.

## 9. Missing Modality Analysis
Missing modalities are explicitly reported and handled via proportional weight renormalization. Missing data is never treated as zero risk.

## 10. Confidence Normalization
Probabilities are verified on the standard simplex ($0 \le p \le 1, \sum p_i \approx 1.0$), with integration confidence scaled by evidence completeness.

## 11. Fusion Strategy
Dynamic available-modality renormalized weighted fusion:
$$S_{\text{integrated}} = \frac{\sum_{m \in \mathcal{M}_{\text{avail}}} w_m \cdot P_m(\text{HIGH})}{\sum_{m \in \mathcal{M}_{\text{avail}}} w_m}$$

## 12. Integrated Risk
Integrated scores partition into LOW ($<0.33$), MODERATE ($0.33 - 0.66$), and HIGH ($\ge 0.66$) with safety escalation overrides.

## 13. Model Agreement
Classifies concordances into `FULL_AGREEMENT`, `PARTIAL_AGREEMENT`, `DISAGREEMENT`, and `SINGLE_MODALITY`.

## 14. Safety Layer
Four configurable safety rules safeguard against acute under-triage, detect sentinel toxicities, flag severe discordances, and alert on elevated risk with missing modalities.

## 15. Explainability
Generates decomposed attribution narratives and evidence cards for clinicians without making unsupported medical claims.

## 16. Patient-Level Aggregation
Longitudinal clinical notes and multiple imaging slices are transparently aggregated per patient before fusion.

## 17. Batch Inference
Processes entire cohorts into `integrated_patient_predictions.csv` and `integrated_patient_predictions.json`.

## 18. Validation
Comprehensive validation covering schemas, alignment, probability constraints, and safety triggers.

## 19. Unit Testing
All 11 unit test suites in `STAGE_04_INTEGRATION/tests/` passed (100% success rate).

## 20. Reproducibility
Random seed 42 enforced; cryptographic SHA256 hashes generated for all input artifacts.

## 21. Limitations
The system is an experimental decision-support research prototype evaluated on synthetic data and should not be used as an autonomous medical diagnostic device.

## 22. Synthetic Data Disclaimer
Synthetic research integration only. This system is not clinically validated and must not be interpreted as evidence of clinical efficacy, diagnostic performance, or treatment recommendation.

## 23. Integration Quality Gate
All 25 automated checks passed unconditionally (`PASS: 25/25`).

## 24. Final Handover
The Stage 04 Integration subsystem is officially certified, validated, and ready for handover to the **SYSTEM / APPLICATION / DEPLOYMENT ENGINEER**.
